je.st
news
Tag: meeting
IRIDEX to Showcase Cyclo G6(TM) Laser System Equipped with MicroPulse Tissue Sparing Glaucoma Technology at American Academy of Ophthalmology (AAO) Meeting
2015-11-17 11:31:13| Industrial Newsroom - All News for Today
Glaucoma System to Make First Ever AAO Appearance at 119th Annual Meeting MOUNTAIN VIEW, Calif., - IRIDEX Corporation (Nasdaq: IRIX) today announced its attendance at the 119(th) annual American Academy of Ophthalmology (AAO) Meeting. The Company will feature its latest product, the Cyclo G6 laser system equipped...
Tags: system
technology
american
meeting
Appendix to Task Force Meeting 6
2015-11-17 01:38:24| PortlandOnline
Noise Task Force Appendix B from November 5, 2015 PDF Document, 269kbCategory: Other Materials
Tags: meeting
force
task
task force
November 18, 2015-Towing Board of Review Meeting Materials
2015-11-16 19:21:18| PortlandOnline
PDF Document, 278kbCategory: Towing News & Events
Tags: november
review
board
meeting
Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting
2015-11-16 14:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the companys C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens a regimen of grazoprevir1, MK-36822 and elbasvir3; and a regimen of grazoprevir, MK-3682 and MK-84084 in treatment-nave patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
results
studies
meeting
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [526] [527] [528] [529] [530] [531] [532] [533] [534] [535] [536] [537] [538] [539] [540] [541] [542] [543] [544] [545] next »